Phage Capsid for Efficient Delivery of Cytotoxic Drugs

Authors: Simona Dostalova, Ana Maria Jimenez Jimenez, Marketa Vaculovicova, Vojtech Adam, Rene Kizek

Abstract:

Various nanomaterials can be used as a drug delivery vehicles in nanomedicine, called nanocarriers. They can either be organic or inorganic, synthetic or natural-based. Although synthetic nanocarriers are easier to produce, they can often be toxic for the organism and thus not suitable for use in treatment. From naturalbased nanocarriers, the most commonly used are protein cages or viral capsids. In this work, virus bacteriophage λ was used for delivery of different cytotoxic drugs (cisplatin, carboplatin, oxaliplatin and doxorubicin). Large quantities of phage λ were obtained from phage λ-producing strain of E. coli cultivated in medium with 0.2% maltose. After killing of E. coli with chloroform and its removal by centrifugation, the phage was concentrated by ultracentrifugation at 130 000×g and 4°C for 3 h. The encapsulation of the drugs was performed by infusion method and four different concentrations of the drugs were encapsulated (200; 100; 50; 25 μg·mL-1). Free drug molecules were removed by filtration. The encapsulation was verified using the absorbance for doxorubicin and atomic absorption spectrometry for platinum cytostatics. The amount of encapsulated drug linearly increased with the increasing concentration of applied drug with the determination coefficient R2=0.989 for doxorubicin; R2=0.967 for cisplatin; R2=0.989 for carboplatin and R2=0.996 for oxaliplatin. The overall encapsulation efficiency was calculated as 50% for doxorubicin; 8% for cisplatin; 6% for carboplatin and 10% for oxaliplatin.

Keywords: Bacteriophage λ, doxorubicin, platinum cytostatics, protein-based nanocarrier, viral capsid.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1110143

References:

[1] Park, K. Facing the truth about nanotechnology in drug delivery. Acs Nano, 2013, vol. 7, no. 9, pp. 7442-7447. ISSN 1936-0851.
[2] Leonard, B. Cancer nanotechnology: going small for big advances: using nanotechnology to advance cancer diagnosis, prevention and treatment. DIANE Publishing Company, 2009. pp. ISBN 9781437912722.
[3] Gu, F. X. et al. Targeted nanoparticles for cancer therapy. Nano Today, 2007, vol. 2, no. 3, pp. 14-21. ISSN 1748-0132.
[4] Chomoucka, J. et al. Magnetic nanoparticles and targeted drug delivering. Pharmacological Research, 2010, vol. 62, no. 2, pp. 144- 149. ISSN 1043-6618.
[5] Peer, D. et al. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2007, vol. 2, no. 12, pp. 751-760. ISSN 1748- 3387.
[6] Sawant, R. M. et al. "SMART" drug delivery systems: Double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjugate Chemistry, 2006, vol. 17, no. 4, pp. 943-949. ISSN 1043-1802.
[7] Dostalova, S. et al. Delivery of doxorubicin using protein nanocarriers. J. Metallomics Nanotech., 2014, vol. 1, no. 4, pp. 34-38. ISSN 2336- 3940.
[8] Dostalova, S. et al. Viral drug nanocarriers. J. Metallomics Nanotech., 2014, vol. 1, no. 1, pp. 30-35. ISSN 2336-3940.
[9] Ma, Y. J. et al. Virus-based nanocarriers for drug delivery. Advanced Drug Delivery Reviews, 2012, vol. 64, no. 9, pp. 811-825. ISSN 0169- 409X.
[10] Steinmetz, N. F. Viral Nanoparticles in Drug Delivery and Imaging. Molecular Pharmaceutics, 2013, vol. 10, no. 1, pp. 1-2. ISSN 1543- 8384.
[11] Lankes, H. A. et al. In vivo gene delivery and expression by bacteriophage lambda vectors. Journal of Applied Microbiology, 2007, vol. 102, no. 5, pp. 1337-1349. ISSN 1364-5072.
[12] Koprowski, H. et al. Human anti-idiotype antibodies in cancer-patients - is the modulation of the immune-response beneficial for the patient. Proceedings of the National Academy of Sciences of the United States of America-Biological Sciences, 1984, vol. 81, no. 1, pp. 216-219. ISSN 0027-8424.
[13] Kaiser, C. R. et al. Biodistribution studies of protein cage nanoparticles demonstrate broad tissue distribution and rapid clearance in vivo. International Journal of Nanomedicine, 2007, vol. 2, no. 4, pp. 715-733. ISSN 1176-9114.
[14] Uchida, M. et al. Biological containers: Protein cages as multifunctional nanoplatforms. Advanced Materials, 2007, vol. 19, no. 8, pp. 1025-1042. ISSN 0935-9648.
[15] Duncan, R. A Sat, Y. N. Tumour targeting by enhanced permeability and retention (EPR) effect. Annals of Oncology, 1998, vol. 9, pp. 39-39. ISSN 0923-7534.
[16] Maeda, H. Macromolecular therapeutics in cancer treatment: The EPR effect and beyond. Journal of Controlled Release, 2012, vol. 164, no. 2, pp. 138-144. ISSN 0168-3659.
[17] Yang, Q. A Catalano, C. E. Biochemical characterization of bacteriophage lambda genome packaging in vitro. Virology, 2003, vol. 305, no. 2, pp. 276-287. ISSN 0042-6822.
[18] Wang, Z. M. et al. Structural studies of several clinically important oncology drugs in complex with human serum albumin. Biochimica Et Biophysica Acta-General Subjects, 2013, vol. 1830, no. 12, pp. 5356- 5374. ISSN 0304-4165.
[19] Dostalova, S. et al. Bacteriophage λ as a doxorubicin nanocarrier J. Metallomics Nanotech., 2014, vol. 1, no. 3, pp. 64-68. ISSN 2336-3940.